India's Glenmark to study potential COVID-19 drug combination
- Country:
- India
Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir as a potential COVID-19 treatment.
The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.
Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.
ALSO READ
-
Japanese Lawmakers Visit India to See Worker Protection and Skills Projects in Action
-
Indian Unions Push for Fair Recruitment and Rights for Care Workers in Germany
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
India's Delicate Balancing Act: Navigating Energy Security Amid Middle Eastern Tensions
Google News